Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

CHADS2 risk score and rate of stroke or systemic embolism and major bleeding in patients with non-valvular atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants.

Van Mieghem W, Lancellotti P.

Acta Cardiol. 2017 Aug;72(4):390-396. doi: 10.1080/00015385.2017.1327248. Epub 2017 Jul 6.

PMID:
28681678
2.

The COMmon control of hypErtenSion and Therapeutic Attitudes in Belgium and Luxemburg study (COME STAI).

van de Borne P, Missault L, Persu A, Van Mieghem W.

Acta Cardiol. 2016 Feb;71(1):35-40. doi: 10.2143/AC.71.1.3132095.

PMID:
26853251
3.

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators.

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.

PMID:
23939297
4.

Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).

Mancia G, Parati G, Bilo G, Gao P, Fagard R, Redon J, Czuriga I, Polák M, Ribeiro JM, Sanchez R, Trimarco B, Verdecchia P, van Mieghem W, Teo K, Sleight P, Yusuf S.

Hypertension. 2012 Dec;60(6):1400-6. doi: 10.1161/HYPERTENSIONAHA.112.199562. Epub 2012 Oct 15.

5.

A critical review on telemonitoring in heart failure.

Gurné O, Conraads V, Missault L, Mullens W, Vachierys JL, Van Mieghem W, Droogne W, Pouleur AC, Troisfontaine P, Huez S, Nellessens E, Peperstraete B, Blouardo P, Vanhaecke J, Raes D; Belgian Working Group on Heart Failure.

Acta Cardiol. 2012 Aug;67(4):439-44. Review.

PMID:
22997998
6.

Stroke prevention in atrial fibrillation: current status and emerging therapies.

Van Mieghem W, Mairesse G, Missault L, Vanhooren G, Verhamme P, Dupont A.

Acta Cardiol. 2012 Apr;67(2):161-7. Review.

PMID:
22641973
7.

Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.

Omboni S, Malacco E, Mallion JM, Volpe M, Zanchetti A; Study Group.

J Hypertens. 2012 Jul;30(7):1468-77. doi: 10.1097/HJH.0b013e32835466ac.

PMID:
22573127
8.

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.

Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S; AVERROES Steering Committee and Investigators.

Lancet Neurol. 2012 Mar;11(3):225-31. doi: 10.1016/S1474-4422(12)70017-0. Epub 2012 Feb 1.

PMID:
22305462
9.

Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF.

Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, Teerlink JR, Greenberg BH, Filippatos G, Teichman SL, Metra M; Pre-RELAX-AHF study group.

Eur J Heart Fail. 2011 Sep;13(9):961-7. doi: 10.1093/eurjhf/hfr060. Epub 2011 May 28.

10.

Irbesartan in patients with atrial fibrillation.

ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ.

N Engl J Med. 2011 Mar 10;364(10):928-38. doi: 10.1056/NEJMoa1008816.

11.

Apixaban in patients with atrial fibrillation.

Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators.

N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10.

12.

Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial.

Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A, Bartunek J, Nienaber C, Macaya C, Peters N, Smits P, Siminiak T, van Mieghem W, Legrand V, Serruys PW.

EuroIntervention. 2011 Feb;6(7):805-12. doi: 10.4244/EIJV6I7A139.

13.

Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.

Mallion JM, Omboni S, Barton J, Van Mieghem W, Narkiewicz K, Panzer PK, Puig JG, Stefanadis C, Zweiker R; Study Group.

Blood Press Suppl. 2011 Apr;1:3-11. doi: 10.3109/08037051.2010.532332. Epub 2010 Nov 23.

PMID:
21091270
14.

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.

Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees.

N Engl J Med. 2010 Oct 7;363(15):1419-28. doi: 10.1056/NEJMoa0912613.

15.

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators.

Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Erratum in: Lancet. 2010 Dec 11;376(9757):1988. Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadán, I Roldan]; Leva, M [corrected to Ieva, M].

PMID:
20801500
16.

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators.

Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X.

PMID:
20709233
17.

Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.

Van Mieghem W, Billiouw JM, Brohet C, Dupont AG, Gazagnes MD, Heller F, Krzesinski JM, Missault L, Persu A, Piérard L, Rottiers R, Vanhooren G, Vervaet P, Herman AG.

Acta Clin Belg. 2010 Mar-Apr;65(2):107-14.

18.

Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.

Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Mansoor GA, Bloomfield DM, Ponikowski P, O'Connor CM, Metra M, Massie BM; PROTECT Steering Committee, Investigators, and Coordinators.

J Card Fail. 2010 Jan;16(1):25-35. doi: 10.1016/j.cardfail.2009.10.025. Epub 2009 Dec 11.

PMID:
20123315
19.

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators.

Lancet. 2009 Nov 28;374(9704):1840-8. doi: 10.1016/S0140-6736(09)61913-9. Epub 2009 Nov 16. Erratum in: Lancet. 2009 Dec 5;374(9705):1888.

PMID:
19922995
20.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M.

N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.

Supplemental Content

Loading ...
Support Center